TI
BCRX icon

Trexquant Investment’s BioCryst Pharmaceuticals BCRX Stock Holding History

Trexquant Investment’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-559,184
Closed -$5.01M – 1593
2025
Q2 		$5.01M Buy
559,184
+169,792
+44% +$1.58M 0.06% 527
2025
Q1 		$2.92M Sell
389,392
-104,964
-21% -$847K 0.03% 727
2024
Q4 		$3.72M Sell
494,356
-386,635
-44% -$2.94M 0.04% 632
2024
Q3 		$6.7M Sell
880,991
-156,180
-15% -$1.19M 0.08% 358
2024
Q2 		$6.41M Buy
1,037,171
+920,238
+787% +$5.08M 0.1% 328
2024
Q1 		$594K Sell
116,933
-304,583
-72% -$1.71M 0.01% 1099
2023
Q4 		$2.52M Sell
421,516
-171,096
-29% -$991K 0.06% 476
2023
Q3 		$4.2M Buy
592,612
+257,094
+77% +$1.85M 0.11% 270
2023
Q2 		$2.36M Buy
335,518
+219,148
+188% +$1.76M 0.06% 444
2023
Q1 		$971K Sell
116,370
-99,890
-46% -$962K 0.03% 742
2022
Q4 		$2.48M Buy
216,260
+109,790
+103% +$1.37M 0.07% 357
2022
Q3 		$1.34M Buy
106,470
+32,958
+45% +$424K 0.05% 449
2022
Q2 		$778K Buy
73,512
+13,359
+22% +$138K 0.03% 624
2022
Q1 		$978K Buy
+60,153
New +$965K 0.05% 481
2021
Q4 		– Sell
-12,632
Closed -$182K – 1295
2021
Q3 		$182K Sell
12,632
-7,451
-37% -$118K 0.01% 977
2021
Q2 		$318K Buy
+20,083
New +$273K 0.03% 684
2017
Q3 		– Sell
-38,432
Closed -$214K – 770
2017
Q2 		$214K Sell
38,432
-12,359
-24% -$75.3K 0.06% 635
2017
Q1 		$427K Buy
50,791
+14,333
+39% +$99.7K 0.05% 602
2016
Q4 		$231K Buy
+36,458
New +$190K 0.04% 758
2015
Q4 		– Sell
-55,279
Closed -$630K – 1009
2015
Q3 		$630K Sell
55,279
-71,021
-56% -$948K 0.05% 631
2015
Q2 		$1.89M Buy
126,300
+103,600
+456% +$1.18M 0.21% 105
2015
Q1 		$204K Buy
+22,700
New +$235K 0.02% 928

Other funds holding BCRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Trexquant Investment's BCRX Position: Q3 2025 in Review

Trexquant Investment sold out of BioCryst Pharmaceuticals (BCRX) in Q3 2025, closing a stake of 559,184 shares — an estimated $5.01M sold.

Trexquant Investment first reported a position in BCRX in Q1 2015 and held it in 22 quarters. The position peaked at $6.7M in Q3 2024. 286 funds tracked by Wall St. Rank hold BCRX as of Q3 2025.

  • Trexquant Investment reported no remaining BioCryst Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Trexquant Investment sold 559,184 BioCryst Pharmaceuticals shares in Q3 2025, an estimated $5.01M.
  • Trexquant Investment first reported a position in BioCryst Pharmaceuticals in Q1 2015 and held it in 22 quarters.
  • Trexquant Investment's BioCryst Pharmaceuticals position peaked at $6.7M in Q3 2024.
  • 286 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q3 2025.

Based on Trexquant Investment's 13F filing for Q3 2025, filed 14 Nov 2025.